Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins
Tim Fessenden(Allen Institute), Stefani Spranger(University of Chicago), Therese Cordero Dumit(Yale University), Irene L. M. Reijers(Oncode Institute), Julian Zulueta(Massachusetts Institute of Technology), Josh Mesfin(Massachusetts Institute of Technology), Esmée P. Hoefsmit(Galapagos (Netherlands)), Fiona Chatterjee(Massachusetts Institute of Technology), Forest M. White(Center for Cancer Research), Christian U. Blank(The Netherlands Cancer Institute), Lauren Stopfer(Io Therapeutics (United States))
Cited by 13
Related Papers
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Phosphoproteome analysis by mass spectrometry and its application to Saccharomyces cerevisiae
|Nature Biotechnology|2002|1.6k
How many human proteoforms are there?
|Nature Chemical Biology|2018|945
Impact of oncogenic pathways on evasion of antitumour immune responses
|Nature reviews. Cancer|2018|652